Anticoagulant treatment and bleeding complications in patients with left ventricular assist devices

References

• Lloyd-Jones D, Lloyd-Jones D, Adams RJ, et al. Heart disease and stroke statistics–2010 update: a report from the American heart association. Circulation. 2010;121(7):e46–e215.
   PubMed Web of Science ®Google Scholar
• Heron M. Deaths: leading causes for 2010. Natl Vital Stat Rep. 2013;62(6):1–96.
   PubMedGoogle Scholar
• Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30–41.
   PubMed Web of Science ®Google Scholar
• Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the flolan international randomized survival trial (FIRST). Am Heart J. 1997;134(1):44–54.
   PubMed Web of Science ®Google Scholar
• Stehlik J, Edwards LB, Kucheryavaya AY, et al. The registry of the international society for heart and lung transplantation: twenty-eighth adult heart transplant report–2011. J Heart Lung Transplant. 2011;30(10):1078–1094.
   PubMedGoogle Scholar
• Lund LH, Khush KK, Cherikh WS, et al. The registry of the international society for heart and lung transplantation: thirty-fourth adult heart transplantation report-2017; Focus theme: allograft ischemic time. J Heart Lung Transplant. 2017;36(10):1037–1046.
   PubMedGoogle Scholar
• Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435–1443.
   PubMed Web of Science ®Google Scholar
• Kirklin JK, Pagani FD, Kormos RL, et al. Eighth annual INTERMACS report: special focus on framing the impact of adverse events. J Heart Lung Transplant. 2017;36(10):1080–1086.
   PubMed Web of Science ®Google Scholar
• Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361(23):2241–2251.
   PubMed Web of Science ®Google Scholar
• Eckman PM, John R. Bleeding and thrombosis in patients with continuous-flow ventricular assist devices. Circulation. 2012;125(24):3038–3047.
   PubMed Web of Science ®Google Scholar
• Akhter SA, Badami A, Murray M, et al. Hospital readmissions after continuous-flow left ventricular assist device implantation: incidence, causes, and cost analysis. Ann Thorac Surg. 2015;100(3):884–889.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Garg L, Shah M, et al. Thirty-day readmissions after left ventricular assist device implantation in the United States: insights from the nationwide readmissions database. Circ Heart Fail. 2018;11(3):e004628.
   PubMed Web of Science ®Google Scholar
• Koval CE, Thuita L, Moazami N, et al. Evolution and impact of drive-line infection in a large cohort of continuous-flow ventricular assist device recipients. J Heart Lung Transplant. 2014;33(11):1164–1172.
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Naftel D, Holman W, et al. Continuous-flow devices and percutaneous site infections: clinical outcomes. J Heart Lung Transplant. 2012;31(11):1151–1157.
   PubMed Web of Science ®Google Scholar
• Maltais S, Kilic A, Nathan S, et al. PREVENtion of Heartmate II pump thrombosis through clinical management: the PREVENT multi-center study. J Heart Lung Transplant. 2017;36(1):1–12.
   PubMed Web of Science ®Google Scholar
• De Jong A, Eikenboom J. Developments in the diagnostic procedures for von Willebrand disease. J Thromb Haemost. 2016;14(3):449–460.
   PubMed Web of Science ®Google Scholar
• Leebeek FW, Eikenboom JC. Von Willebrand’s disease. N Engl J Med. 2016;375(21):2067–2080.
   PubMed Web of Science ®Google Scholar
• Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand’s disease. J Clin Invest. 1977;60(2):390–404.
   PubMed Web of Science ®Google Scholar
• Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood. 1994;83(8):2171–2179.
   PubMed Web of Science ®Google Scholar
• Hollestelle MJ, LOOTS CM, SQUIZZATO A, et al. Decreased active von Willebrand factor level owing to shear stress in aortic stenosis patients. J Thromb Haemost. 2011;9(5):953–958.
   PubMed Web of Science ®Google Scholar
• Klovaite J, Gustafsson F, Mortensen SA, et al. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol. 2009;53(23):2162–2167.
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Yamamoto Y, Okamatsu H, et al. D-dimer is helpful for differentiating acute aortic dissection and acute pulmonary embolism from acute myocardial infarction. Hellenic J Cardiol. 2011;52(2):123–127.
   PubMed Web of Science ®Google Scholar
• Meyer AL, Malehsa D, Budde U, et al. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail. 2014;2(2):141–145.
   PubMed Web of Science ®Google Scholar
• Goda M, Jacobs S, Rega F, et al. Time course of acquired von Willebrand disease associated with two types of continuous-flow left ventricular assist devices: Heartmate II and circulate synergy pocket micro-pump. J Heart Lung Transplant. 2013;32(5):539–545.
   PubMed Web of Science ®Google Scholar
• Meyer AL, Malehsa D, Bara C, et al. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail. 2010;3(6):675–681.
   PubMed Web of Science ®Google Scholar
• Starke RD, Ferraro F, Paschalaki KE, et al. Endothelial von Willebrand factor regulates angiogenesis. Blood. 2011;117(3):1071–1080.
   PubMed Web of Science ®Google Scholar
• Makris M, Federici AB, Mannucci PM, et al. The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease. Haemophilia. 2015;21(3):338–342.
   PubMed Web of Science ®Google Scholar
• Randi AM, Laffan MA. Von Willebrand factor and angiogenesis: basic and applied issues. J Thromb Haemost. 2017;15(1):13–20.
   PubMed Web of Science ®Google Scholar
• Demirozu ZT, Radovancevic R, Hochman LF, et al. Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2011;30(8):849–853.
   PubMed Web of Science ®Google Scholar
• Broos K, Feys HB, De Meyer SF, et al. Platelets at work in primary hemostasis. Blood Rev. 2011;25(4):155–167.
   PubMed Web of Science ®Google Scholar
• Hu J, Mondal NK, Sorensen EN, et al. Platelet glycoprotein Ibalpha ectodomain shedding and non-surgical bleeding in heart failure patients supported by continuous-flow left ventricular assist devices. J Heart Lung Transplant. 2014;33(1):71–79.
   PubMed Web of Science ®Google Scholar
• Steinlechner B, Dworschak M, Birkenberg B, et al. Platelet dysfunction in outpatients with left ventricular assist devices. Ann Thorac Surg. 2009;87(1):131–137.
   PubMed Web of Science ®Google Scholar
• Mondal NK, Li T, Chen Z, et al. Mechanistic insight of platelet apoptosis leading to non-surgical bleeding among heart failure patients supported by continuous-flow left ventricular assist devices. Mol Cell Biochem. 2017;433(1–2):125–137.
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, John R, Salerno C, et al. Algorithm for the diagnosis and management of suspected pump thrombus. J Heart Lung Transplant. 2013;32(7):667–670.
   PubMed Web of Science ®Google Scholar
• Lazar RM, Shapiro PA, Jaski BE, et al. Neurological events during long-term mechanical circulatory support for heart failure: the randomized evaluation of mechanical assistance for the treatment of congestive heart failure (REMATCH) experience. Circulation. 2004;109(20):2423–2427.
   PubMed Web of Science ®Google Scholar
• Starling RC, Moazami N, Silvestry SC, et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med. 2014;370(1):33–40.
   PubMed Web of Science ®Google Scholar
• Najjar SS, Slaughter MS, Pagani FD, et al. An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. J Heart Lung Transplant. 2014;33(1):23–34.
   PubMed Web of Science ®Google Scholar
• Schmitto JD, Hanke JS, Rojas SV, et al. First implantation in man of a new magnetically levitated left ventricular assist device (HeartMate III). J Heart Lung Transplant. 2015;34(6):858–860.
   PubMed Web of Science ®Google Scholar
• Mehra MR, Uriel N, Naka Y, et al. A fully magnetically levitated left ventricular assist device — final report. N Engl J Med. 2019;380(17):1618–1627.
   PubMed Web of Science ®Google Scholar
• Shah P, Mehta VM, Cowger JA, et al. Diagnosis of hemolysis and device thrombosis with lactate dehydrogenase during left ventricular assist device support. J Heart Lung Transplant. 2014;33(1):102–104.
   PubMed Web of Science ®Google Scholar
• Uriel N, Morrison KA, Garan AR, et al. Development of a novel echocardiography ramp test for speed optimization and diagnosis of device thrombosis in continuous-flow left ventricular assist devices: the Columbia ramp study. J Am Coll Cardiol. 2012;60(18):1764–1775.
   PubMed Web of Science ®Google Scholar
• Feldman D, Pamboukian SV, Teuteberg JJ, et al. The 2013 international society for heart and lung transplantation guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013;32(2):157–187.
   PubMed Web of Science ®Google Scholar
• Slaughter MS, Naka Y, John R, et al. Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. J Heart Lung Transplant. 2010;29(6):616–624.
   PubMed Web of Science ®Google Scholar
• Sandner SE, Riebandt J, Haberl T, et al. Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation. J Heart Lung Transplant. 2014;33(1):88–93.
   PubMed Web of Science ®Google Scholar
• Adatya S, Sunny R, Fitzpatrick MJ, et al. Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices. J Heart Lung Transplant. 2016;35(11):1311–1320.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg. 2003;76(6):2121–2131.
   PubMed Web of Science ®Google Scholar
• Koster A, Huebler S, Potapov E, et al. Impact of heparin-induced thrombocytopenia on outcome in patients with ventricular assist device support: single-institution experience in 358 consecutive patients. Ann Thorac Surg. 2007;83(1):72–76.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: american college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):340S–380S.
   PubMed Web of Science ®Google Scholar
• Jennings DL, Brewer R, Williams C. Impact of continuous flow left ventricular assist device on the pharmacodynamic response to warfarin early after implantation. Ann Pharmacother. 2012;46(9):1266–1267.
   PubMed Web of Science ®Google Scholar
• Jennings D, McDonnell J, Schillig J. Assessment of long-term anticoagulation in patients with a continuous-flow left-ventricular assist device: a pilot study. J Thorac Cardiovasc Surg. 2011;142(1):e1–2.
   PubMed Web of Science ®Google Scholar
• Argiriou M, Kolokotron, SM, Sakellaridis, T, et al. Right heart failure post left ventricular assist device implantation. J Thorac Dis. 2014;6(Suppl 1):S52–9.
   PubMedGoogle Scholar
• Visser LE, Bleumink GS, Trienekens PH, et al. The risk of over anticoagulation in patients with heart failure on coumarin anticoagulants. Br J Haematol. 2004;127(1):85–89.
   PubMed Web of Science ®Google Scholar
• Nassif ME, LaRue, SJ, Raymer, DS, et al. Relationship between anticoagulation intensity and thrombotic or bleeding outcomes among outpatients with continuous-flow left ventricular assist devices. Circ Heart Fail. 2016;9(5):e002680.
   PubMed Web of Science ®Google Scholar
• Grabska J, Schlöglhofer T, Gross C, et al. Early detection of pump thrombosis in patients with left ventricular assist device. ASAIO J. 2020;66(4):348–354.
   Google Scholar
• Bhatia A, Juricek C, Sarswat N, et al. Increased risk of bleeding in left ventricular assist device patients treated with enoxaparin as bridge to therapeutic international normalized ratio. Asaio J. 2018;64(2):140–146.
   PubMed Web of Science ®Google Scholar
• Cosgrove RH, Basken RL, Smith RG, et al. Anticoagulant bridge comparison in mechanical circulatory support patients. Asaio J. 2019;65(1):54–58.
   PubMed Web of Science ®Google Scholar
• Schettle S, Schlöglhofer T, Zimpfer D, et al. International analysis of LVAD point-of-care versus plasma INR: A multicenter study. Asaio J. 2018;64(6):e161–e165. DOI:10.1097/MAT.0000000000000845.
   PubMed Web of Science ®Google Scholar
• Es van J, EERENBERG ES, KAMPHUISEN PW, et al. How to prevent, treat, and overcome current clinical challenges of VTE. J Thromb Haemost. 2011;9(Suppl 1):265–274.
   PubMedGoogle Scholar
• van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124(12):1968–1975.
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. Bmj. 2017;359:j5058.
   PubMedGoogle Scholar
• Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110(3):453–460.
   PubMed Web of Science ®Google Scholar
• van der Hulle T, Kooiman J, den Exter PL, et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12(3):320–328.
   PubMed Web of Science ®Google Scholar
• Andreas M, Moayedifar, R, Wieselthaler, G, et al. Increased thromboembolic events with dabigatran compared with vitamin K antagonism in left ventricular assist device patients: A randomized controlled pilot trial. Circ Heart Fail. 2017;10(5):e003709.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206–1214.
   PubMed Web of Science ®Google Scholar
• Dewanjee MK, Gross DR, Zhai P, et al. Thrombogenicity of polyethylene oxide-bonded Dacron sewing ring in a mechanical heart valve. J Heart Valve Dis. 1999;8(3):324–330.
   PubMed Web of Science ®Google Scholar
• Pollari F, Fischlein T, Fittkau M, et al. Anticoagulation with apixaban in a patient with a left ventricular assist device and gastrointestinal bleeding: A viable alternative to warfarin? J Thorac Cardiovasc Surg. 2016;151(4):e79–81.
   PubMed Web of Science ®Google Scholar
• Baumann Kreuziger LM, Kim B, Wieselthaler GM. Antithrombotic therapy for left ventricular assist devices in adults: a systematic review. J Thromb Haemost. 2015;13(6):946–955.
   PubMed Web of Science ®Google Scholar
• Netuka I, Litzler P-Y, Berchtold-Herz M, et al. Outcomes in HeartMate II patients with no antiplatelet therapy: 2-year results from the European TRACE study. Ann Thorac Surg. 2017;103(4):1262–1268.
   PubMed Web of Science ®Google Scholar
• Stulak JM, Cowger J, Haft JW, et al. Device exchange after primary left ventricular assist device implantation: indications and outcomes. Ann Thorac Surg. 2013;95(4):1262–1267; discussion 1267–8.
   PubMed Web of Science ®Google Scholar
• Muthiah K, Robson D, Macdonald PS, et al. Thrombolysis for suspected intrapump thrombosis in patients with continuous flow centrifugal left ventricular assist device. Artif Organs. 2013;37(3):313–318.
   PubMed Web of Science ®Google Scholar
• Kamouh A, John R, Eckman P. Successful treatment of early thrombosis of HeartWare left ventricular assist device with intraventricular thrombolytics. Ann Thorac Surg. 2012;94(1):281–283.
   PubMed Web of Science ®Google Scholar
• Delgado R 3rd, Frazier OH, Myers TJ, et al. Direct thrombolytic therapy for intraventricular thrombosis in patients with the Jarvik 2000 left ventricular assist device. J Heart Lung Transplant. 2005;24(2):231–233.
   PubMed Web of Science ®Google Scholar
• Hayes H, Dembo L, Larbalestier R, et al. Successful treatment of ventricular assist device associated ventricular thrombus with systemic tenecteplase. Heart Lung Circ. 2008;17(3):253–255.
   PubMed Web of Science ®Google Scholar
• Joy PS, Kumar G, Guddati AK, et al. Risk factors and outcomes of gastrointestinal bleeding in left ventricular assist device recipients. Am J Cardiol. 2016;117(2):240–244.
   PubMed Web of Science ®Google Scholar
• Draper KV, Huang RJ, Gerson LB. GI bleeding in patients with continuous-flow left ventricular assist devices: a systematic review and meta-analysis. Gastrointest Endosc. 2014;80(3):435–446.e1.
   PubMed Web of Science ®Google Scholar
• Tabit CE, Chen P, Kim GH, et al. Elevated angiopoietin-2 level in patients with continuous-flow left ventricular assist devices leads to altered angiogenesis and is associated with higher nonsurgical bleeding. Circulation. 2016;134(2):141–152.
   PubMed Web of Science ®Google Scholar
• Sarode R, Milling TJ, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234–1243.
   PubMed Web of Science ®Google Scholar
• Goldstein JN, Refaai MA, Milling TJ, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385(9982):2077–2087.
   PubMed Web of Science ®Google Scholar
• Rimsans J, Levesque A, Lyons E, et al. Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices. J Thromb Thrombolysis. 2018;46(2):180–185.
   PubMed Web of Science ®Google Scholar
• Jennings DL, Rimsans J, Connors JM. Prothrombin Complex Concentrate for Warfarin Reversal in Patients with Continuous-Flow Left Ventricular Assist Devices: A Narrative Review. Asaio J. 2019.
   PubMedGoogle Scholar
• Gurvits GE, Fradkov E. Bleeding with the artificial heart: gastrointestinal hemorrhage in CF-LVAD patients. World J Gastroenterol. 2017;23(22):3945–3953.
   PubMed Web of Science ®Google Scholar
• Marsano J, Desai J, Chang S, et al. Characteristics of gastrointestinal bleeding after placement of continuous-flow left ventricular assist device: a case series. Dig Dis Sci. 2015;60(6):1859–1867.
   PubMed Web of Science ®Google Scholar
• Muslem R, Caliskan K, Leebeek FWG. Acquired coagulopathy in patients with left ventricular assist devices. J Thromb Haemost. 2018;16(3):429–440.
   PubMed Web of Science ®Google Scholar
• Fischer Q, Huisse M-G, Voiriot G, et al. Von Willebrand factor, a versatile player in gastrointestinal bleeding in left ventricular assist device recipients? Transfusion. 2015;55(1):51–54.
   PubMed Web of Science ®Google Scholar
• Loyaga-Rendon RY, Hashim T, Tallaj JA, et al. Octreotide in the management of recurrent gastrointestinal bleed in patients supported by continuous flow left ventricular assist devices. Asaio J. 2015;61(1):107–109.
   PubMed Web of Science ®Google Scholar
• Wever-Pinzon O, Selzman CH, Drakos SG, et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail. 2013;6(3):517–526.
   PubMed Web of Science ®Google Scholar
• Netuka I, Kvasnička T, Kvasnička J, et al. Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure. J Heart Lung Transplant. 2016;35(7):860–867.
   PubMed Web of Science ®Google Scholar
• Backes D, van den Bergh WM, van Duijn AL, et al. Cerebrovascular complications of left ventricular assist devices. ASAIO J. 2020;66(5):482–488.
   Google Scholar
• Wilson TJ, Stetler WR, Al-Holou WN, et al. Management of intracranial hemorrhage in patients with left ventricular assist devices. J Neurosurg. 2013;118(5):1063–1068.
   PubMed Web of Science ®Google Scholar
• Santos CD, Matos NL, Asleh R, et al. The dilemma of resuming antithrombotic therapy after intracranial hemorrhage in patients with left ventricular assist devices. Neurocrit Care. 2019. DOI:10.1007/s12028-019-00836-y.
   Web of Science ®Google Scholar
• Ramey WL, Basken RL, Walter CM, et al. Intracranial hemorrhage in patients with durable mechanical circulatory support devices: institutional review and proposed treatment algorithm. World Neurosurg. 2017;108:826–835.
   PubMed Web of Science ®Google Scholar